Oral bovine Lf administration has been demonstrated to be useful in preterm newborns at risk of sepsis and to modulate gut microbiota and could therefore be a safe adjunctive strategy that deserves to be studied in newborns with CGISCs in large, well-conducted trials. The gene discussed is LTF; the disease is Sepsis.